ERBB2 and breast cancer: Trastuzumab (trade name Herceptin®, Genentech, South San Francisco, CA, USA) is a fully humanized anti-HER2 monoclonal antibody approved by Food and Drug Administration (FDA) for the treatment of HER2+ BC [70,71].